Vidofludimus calcium is a small molecule commercialized by Immunic, with a leading Phase III program in Relapsing Remitting Multiple Sclerosis (RRMS). According to Globaldata, it is involved in 13 clinical trials, of which 9 were completed, 3 are ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Vidofludimus calcium’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Vidofludimus calcium is expected to reach an annual total of $864 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Vidofludimus calcium Overview
Vidofludimus calcium (IMU-838) is under development for the treatment of relapsing-remitting multiple sclerosis, progressive multiple sclerosis and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), primary progressive multiple sclerosis (ppms) and secondary progressive multiple sclerosis (spms). The drug candidate is administered by oral route. It is a calcium salt of vidofludimus. It targets dihydroorotate dehydrogenase (DHODH) andNurr1 (Nuclear receptor related 1). It was under development for the treatment of ulcerative colitis, primary sclerosing cholangitis and crohn's disease.
Immunic (Immunic Therapeutics) is a biopharmaceutical company that discover, develops and commercializes oral immunology therapies to treat chronic inflammatory and autoimmune diseases. The company’s pipeline products include IMU-838, a selective immune modulator for the treatment of relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), other chronic inflammatory and autoimmune diseases; IMU-856, an orally small molecule modulator to treat intestinal barrier function; and IMU-935, an immunology therapy targeting ROR?t and Th17. It also evaluating therapies targeting primary sclerosing cholangitis (PSC) and guillain-barre syndrome (GBS).The company has operations in Germany, Australia and the US. Immunic Therapeutics is headquartered in New York City, New York, the US.
The operating loss of the company was US$119.5 million in FY2022, compared to an operating loss of US$91.7 million in FY2021. The net loss of the company was US$120.4 million in FY2022, compared to a net loss of US$92.9 million in FY2021.
For a complete picture of Vidofludimus calcium’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.